Study Chair

Andrew A Nierenberg, MD

Harvard Medical School (HMS and HSDM)

  • 4 trials
  • 1 compound

Therapeutic focus

  • Bipolar Depression
  • Suicidal Ideation and Behavior
  • Bipolar Disorder
  • Major Depressive Disorder

All trials (4)

NCTPhaseStatusCompoundSponsor
NCT03395392Phase 2/3CompletedNRX-101 (D-cycloserine/lurasidone)
NCT01331304Phase 4Completed—
NCT00731653Phase 2Completed—
NCT00705003Phase 2Completed—

Compounds studied

Trial sites (30)

  • Pittsburgh, Pennsylvania, United States
  • Decatur, Georgia, United States
  • Dallas, Texas, United States
  • Nashville, Tennessee, United States
  • Culver City, California, United States
  • Omaha, Nebraska, United States
  • Birmingham, Alabama, United States
  • Cleveland, Ohio, United States
  • Amherst, New York, United States
  • Mason, Ohio, United States
  • Richmond, Texas, United States
  • Ann Arbor, Michigan, United States
  • Savannah, Georgia, United States
  • Houston, Texas, United States
  • Austin, Texas, United States
  • Garden Grove, California, United States
  • Atlanta, Georgia, United States
  • Gaithersburg, Maryland, United States
  • New York, New York, United States
  • San Diego, California, United States
  • San Antonio, Texas, United States
  • Rockville, Maryland, United States
  • Stanford, California, United States
  • Beachwood, Ohio, United States
  • Fort Worth, Texas, United States
  • Philadelphia, Pennsylvania, United States
  • Miami Lakes, Florida, United States
  • Eugene, Oregon, United States
  • Boston, Massachusetts, United States
  • Altanta, Georgia, United States

Investigator and site data mirrored fromClinicalTrials.gov (public domain).